Biomatter secures $18 million series A funding to accelerate custom enzyme design

We are proud to share that CLIB member Biomatter has successfully closed an $18 million Series A financing round, led by Astanor Ventures, with existing investors UVC Partners, Inventure, and Metaplanet also participating.
Founded in 2018, Biomatter is developing a novel approach to enzyme engineering. Rather than optimising naturally occurring enzymes, the company designs enzymes from scratch to perform specific reactions required by customers. Its long-term vision is to make tailor-made enzymes as accessible as off-the-shelf products, enabling industrial and biotechnological processes that were previously not commercially feasible.
The technology has already reached commercial application. One example is Thermo Fisher Scientific’s Invitrogen SuperScript™ V Reverse Transcriptase, which incorporates a Biomatter-designed enzyme with enhanced oxidation resistance, allowing the reagent to be stored and transported at room temperature.
To date, Biomatter has delivered more than 50 custom enzymes for over 25 industrial customers, including companies such as AstraZeneca, BASF, Kirin Holdings, Neogen, Sanofi, and Tereos. Among its innovations is a methylase developed for mRNA manufacturing that operates without S-adenosyl methionine (SAM), a costly cofactor required by naturally occurring methylases.
The new investment will support the construction of a new design and testing facility in Vilnius, the expansion of Biomatter’s commercial team, and a stronger presence in the United States. The company also aims to further accelerate its development cycles, which already enable enzyme design projects to be completed within weeks rather than months or years.
We are happy to see Biomatter achieve this important milestone and are proud to count them in the CLIB network. Those of our members who were present at the CLIB Networking Day CND2026 in Bergkamen on 03 November have already seen a presentation of the Biomatter’s approach and product examples by CEO Laurynas Karpus.
Congratulations to the entire Biomatter team on this achievement!

